Table 1 Patients characteristics.

From: CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program

Variable

N (%)

Age

<70 years

51 (71.8)

>70 years

20 (28.2)

Sex

Male

39 (54.9)

Female

32 (45.1)

WBC

<30 × 109/L

60 (84.5)

>30 × 109/L

11 (15.5)

Marrow blasts

<30%

22 (31.0)

>30%

49 (69.0)

Previous HMA

No

54 (76.1)

Yes

17 (23.9)

NPM1 (evaluated in 68/71, 96%)

Wild type

63 (92.7)

Mutated

5 (7.3)

FLT3-ITD (evaluated in 69/71, 97%)

Negative

64 (92.8)

Positive

5 (7.2)

TP53 (evaluated in 37/71, 52%)

Wild type

24 (64.9)

Mutated

13 (35.1)

Karyotype

Favorable

3 (4.7)

Intermediate

36 (50.2)

Poor

32 (45.1)

CPX-351 indication

s-AML

36 (50.2)

t-AML

22 (31.0)

MDS-related changes

13 (18.8)

ELN 2017

Low/Int.

8 (11.3)

Intermediate

24 (33.8)

High

39 (54.9)

Back to article page